Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country.
"This provision would be live from August 12," Union Health Secretary Rajesh Bhushan said in a letter to states and Union territories.
He said that Corbevax will be available as precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines for population above 18 years.
"This enables use of Corbevax as a heterologous COVID-19 vaccine for precaution dose administration in this age group," Bhushan said.
There will be no change in existing guidelines for homologous precaution dose administration of Covaxin and Covishield, he said.
The decision has been taken based on scientific evidence, global practices and the recommendations of domain knowledge experts.
India's COVID-19 vaccination program has achieved the historical milestone of administering more than 2 billion doses so far.
About 97 per cent of the 12 plus age population of the country has been covered with at least one dose and about 89 per cent with both doses. 
 

Govt approves use of Corbevax as a booster dose for adults

This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country.

This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country.

The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country.
The concept of heterologous booster dose implies the use of a different vaccine from what was used for a primary dose. While under the homologous booster vaccine concept, a person is injected the same vaccine that was used for the previous doses.
"This provision would be live from August 12," Union Health Secretary Rajesh Bhushan said in a letter to states and Union territories.
He said that Corbevax will be available as precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines for population above 18 years.
Also Watch| <a href="https://www.editorji.com/coronavirus/india-crosses-mega-200-crore-covid-vaccine-milestone-1658040665735">India crosses mega 200-crore Covid vaccine milestone</a>
"This enables use of Corbevax as a heterologous COVID-19 vaccine for precaution dose administration in this age group," Bhushan said.
There will be no change in existing guidelines for homologous precaution dose administration of Covaxin and Covishield, he said.
The decision has been taken based on scientific evidence, global practices and the recommendations of domain knowledge experts.
India's COVID-19 vaccination program has achieved the historical milestone of administering more than 2 billion doses so far.
About 97 per cent of the 12 plus age population of the country has been covered with at least one dose and about 89 per cent with both doses.&nbsp;

Biological E Limited on Saturday announced that its COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India (DCGI) as a heterologous booster dose.
A press release from the vaccine maker said the Corbevax can be administered as a booster dose to individuals aged 18 years and above after six months of administration of primary vaccination (two doses) of Covaxin or Covishield vaccines for restricted use in emergency situation.
BE's Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster in the country, it said.
Recently, BE furnished its clinical trials data to the DCGI which after a detailed evaluation and deliberations with Subject Experts Committee, granted their approval for administering Corbevax as a heterologous booster dose to people who have been vaccinated.
BE's clinical trial data showed that its Corbevax booster dose provided significant enhancement in immune response and excellent safety profile required for an effective booster.
Mahima Datla, Managing Director, Biological E Limited, said, "We are very happy with this approval, which will address the need for COVID-19 booster doses in India. We have crossed yet another milestone in our COVID-19 vaccination journey. This approval reflects once again the sustained world-class safety standards and high immunogenicity of Corbevax." BE has conducted a multi-centre Phase-III placebo controlled heterologous booster clinical trial in 416 subjects from 18 to 80 years of age who were previously vaccinated with two doses of either Covishield or Covaxin at least six months prior to the administration of Corbevax as a booster, the release added.
Corbevax is entirely developed and manufactured by BE Limited in association with Texas Children's Hospital and Baylor College of Medicine as a recombinant protein sub-unit vaccine against COVID-19.
BE has supplied 100 million doses of the jab to the Central government so far. 

Biological E's Corbevax approved Covid-19 booster dose for 18 and above in India

Biological E Limited on Saturday announced that its Covid-19 vaccine Corbevax has been approved by the Drug Controller General of India  as a heterologous booster dose.

BE's Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster in the country

Biological E Limited on Saturday announced that its COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India (DCGI) as a heterologous booster dose.
A press release from the vaccine maker said the Corbevax can be administered as a booster dose to individuals aged 18 years and above after six months of administration of primary vaccination (two doses) of Covaxin or Covishield vaccines for restricted use in emergency situation.
BE's Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster in the country, it said.
Recently, BE furnished its clinical trials data to the DCGI which after a detailed evaluation and deliberations with Subject Experts Committee, granted their approval for administering Corbevax as a heterologous booster dose to people who have been vaccinated.
BE's clinical trial data showed that its Corbevax booster dose provided significant enhancement in immune response and excellent safety profile required for an effective booster.
Mahima Datla, Managing Director, Biological E Limited, said, "We are very happy with this approval, which will address the need for COVID-19 booster doses in India. We have crossed yet another milestone in our COVID-19 vaccination journey. This approval reflects once again the sustained world-class safety standards and high immunogenicity of Corbevax." BE has conducted a multi-centre Phase-III placebo controlled heterologous booster clinical trial in 416 subjects from 18 to 80 years of age who were previously vaccinated with two doses of either Covishield or Covaxin at least six months prior to the administration of Corbevax as a booster, the release added.
Corbevax is entirely developed and manufactured by BE Limited in association with Texas Children's Hospital and Baylor College of Medicine as a recombinant protein sub-unit vaccine against COVID-19.
BE has supplied 100 million doses of the jab to the Central government so far.&nbsp;
Also Watch| <a href="https://www.editorji.com/coronavirus/covaxin-gets-emergency-use-nod-for-6-12-age-group-1650960309414" target="_blank">Covid-19: Covaxin gets emergency use nod for 6-12 age group</a>

corbevax

Categories